That opens the door for broader access to Zepbound, which is not currently covered by Medicare and many other insurance plans for weight loss. Demand for the injection has soared over the last year ...
Important Milestone Clears the Way for Millions of Medicare Beneficiaries with Sleep Apnea to Access Vivos’ Patented and FDA-Cleared Oral Appliance Treatment LITTLETON, Colo., July 01, 2025 (GLOBE ...
SAN FRANCISCO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision oral appliance therapy (OAT) for the treatment of Obstructive Sleep Apnea (OSA), ...
Zepbound (tirzepatide) is a type of drug called a glucagon-like peptide-1 (GLP-1) receptor agonist. It has the same active ingredient as the type 2 diabetes medication Mounjaro. The Food and Drug ...
Vivos Therapeutics Inc. (NASDAQ:VVOS) saw its stock soar by 90% following a major regulatory win: the company’s VidaSleep oral appliance has secured approval from the Centers for Medicare & Medicaid ...
Vivos Therapeutics shares were 24% higher, at $3.91, after the company said its VidaSleep oral appliance was approved by the Centers for Medicare & Medicaid Services Pricing, Data Analysis and Coding ...
Medicare Part D coverage of glucagon-like peptide-1 receptor agonists— widely prescribed for diabetes and increasingly sought for obesity and related conditions— has remained broad. A research letter ...
LITTLETON, Colo., July 01, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (VVOS) (“Vivos” or the “Company”), a pioneering medical technology company revolutionizing the treatment of obstructive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback